Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 8Carcinoma, Non-Small-Cell Lung 7Small Cell Lung Carcinoma 6Squamous Cell Carcinoma of Head and Neck 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Carcinoma, Renal Cell 3Biliary Tract Neoplasms 3Advanced Solid Tumors 3Vulvar Neoplasms 2Vaginal Neoplasms 2Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Solid Tumor 1Solid Malignancies 1Peritoneal Neoplasms 1Part A and B: Advanced Solid Malignancies 1Neoplasms 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

tremelimumab 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Malignancy × tremelimumab × Clear all
NCT02978482 2021-08-18

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

AstraZeneca

Phase 1 Completed
26 enrolled

Advanced Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡